Substituted N-arylheterocycles, method for production and use thereof as medicaments

Details for Australian Patent Application No. 2004212145 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Hessler, Gerhard; Gretzke, Dirk; Stengelin, Siegfried; Bohme, Thomas; Stahl, Petra; Gossel, Matthias; Schwink, Lothar

Agent Watermark

Pub. Number AU-B-2004212145

PCT Pub. Number WO2004/072025

Priority 103 06 250.5 14.02.03 DE

Filing date 13 February 2004

Wipo publication date 26 August 2004

Acceptance publication date 17 June 2010

International Classifications

C07D 207/14 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

C07D 205/04 (2006.01) Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom

C07D 207/16 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 207/26 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 207/34 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 211/58 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 409/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

8 September 2005 PCT application entered the National Phase

  PCT publication WO2004/072025 Priority application(s): WO2004/072025

5 January 2006 Change of Name(s) of Applicant(s), Section 104

  Aventis Pharma Deutschland GmbH The name of the applicant has been changed to Sanofi-Aventis Deutschland GmbH

17 June 2010 Application Accepted

  Published as AU-B-2004212145

14 October 2010 Standard Patent Sealed

8 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004212151-Heterocyclic compounds useful as Nurr-1 activators

2004212140-Benzamide derivatives as oxytocin agonists and vasopressin antagonists